Prothena Corporation plc (PRTA)
$56.71
Rating:
Recommendation:
Buy
| Symbol | PRTA |
|---|---|
| Price | $56.71 |
| Beta | 0.481 |
| Volume Avg. | 0.83M |
| Market Cap | 2.743B |
| Shares () | - |
| 52 Week Range | 21.06-65.35 |
| 1y Target Est | - |
| DCF Unlevered | PRTA DCF -> | |
|---|---|---|
| DCF Levered | PRTA LDCF -> | |
| ROE | -36.46% | Strong Sell |
| ROA | -28.22% | Sell |
| Operating Margin | - | |
| Debt / Equity | 37.02% | Neutral |
| P/E | 38.58 | Strong Buy |
| P/B | 6.58 | Strong Buy |
Latest PRTA news
About
Download (Excel)Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.